“Alzheimer’s disease Pipeline” has been added to DelveInsight
Alzheimer’s disease Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitors, launch date along with product development activities.
DelveInsight’s, “Alzheimer’s Disease Pipeline Insights, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download free sample copy here– https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight
Alzheimer’s disease Overview
Alzheimer’s disease is a debilitating neurological disorder that gradually erodes memory and cognitive abilities, as well as the ability to perform even the most basic tasks. Alzheimer’s patients have difficulty doing simple tasks such as driving a car, preparing a meal, or paying bills. They can repeatedly ask the same questions, become easily disoriented, accidentally drop or misplace objects, and find even simple things perplexing. Some people become worried, frustrated, or aggressive as the disease progresses.
Alzheimer’s disease Key Players
- Eisai
- Biogen
- Changchun Huayang High-tech Co. Ltd.
- Hoffmann-La Roche
- vTv Therapeutics
- AZTherapies
- Cerecin
- Neurotrope
- Lyndra
- AC Immune
- INmune Bio
- Cassava Sciences
- EIP Pharma
- Neuraly
- AB Science
- Cortexyme
- Anavex Life Sciences
- Athira Pharma
- Time Therapeutics
- Prilenia Therapeutics
- Denali Therapeutics Inc.
Alzheimer’s disease Drugs
- BAN2401
- Elenbecestat (E2609)
- Octohydroaminoacridine Succinate
- Gantenerumab
- Azeliragon (TTP488)
- ALZT-OP1
- AZT-211
- Tricaprilin
- Bryostatin-1
- Donepezil/memantine extended release
- ACI-3024
- INB03
- Sumifilam
- Neflamapimod
- Pegylated exenatide
- Masitinib
- Atuzaginstat
- Blarcamesine
- NDX-1017
- Bromocriptine
- Pridopidine
- DNL788
Alzheimer’s disease Emerging Therapy Assessment
The dynamics of the Alzheimer’s disease market is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as Eisai/ BioArctic AB, Biogen, Hoffmann-La Roche/Chugai Pharmaceuticals, Anavex Life Sciences Corp., Neurimmune and others are involved in developing drugs for Alzheimer’s disease.
Alzheimer’s disease Symptoms
- Cognitive deficits.
- Problems with recognition
- Problems with spatial awareness
- Problems with speaking, reading, or writing
- Later symptoms include impaired communication, disorientation, confusion, poor judgment, behavioral changes and, ultimately, difficulty speaking, swallowing and walking.
- As the disease progresses, neurons in other parts of the brain are damaged or destroyed.
Alzheimer’s disease Diagnosis
A diagnosis of Alzheimer’s disease (AD) is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Means of diagnosing AD include clinical diagnosis which is usually made during the mild stage of the disease, Lumbar puncture, and Imaging studies.
Alzheimer’s disease Treatment
Treatment for Alzheimer’s disease (AD) includes options that may reduce the symptoms and help improve the quality of life. The U.S. Food and Drug Administration (FDA) has approved two types of medications — cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda) to treat the cognitive symptoms. Other non-pharmacological therapies are also used with the goal of maintaining or improving cognitive function, the ability to perform activities of daily living or overall quality of life.
Alzheimer’s disease Emerging Drugs
BAN2401: Eisai
BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils. BAN2401 selectively binds to neutralize and eliminate toxic Aβ protofibrils that are thought to be a causative factor for Alzheimer’s disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic in December 2007.
Gantenerumab: Hoffmann-La Roche
Gantenerumab is an investigational therapy designed to bind more specifically to aggregated forms of beta-amyloid and remove beta-amyloid plaques. Gantenerumab was originally developed by Chugai Pharmaceuticals, which is now part of Hoffmann-La Roche. This treatment is administered as an injection under the skin, is now being developed by Hoffmann-La Roche in collaboration with MorphoSys.
Alzheimer’s disease Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Alzheimer’s disease (AD) R&D. The therapies under development are focused on novel approaches to treat/improve Alzheimer’s disease (AD).
- In December 2019, BioArctic announced the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401. The research collaboration with Eisai is in addition to the existing development and commercialization agreement for BAN2401. This new collaboration is intended to further characterize the unique binding profile of BAN2401.
Download free sample copy here- https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight
Following is the TOC of Alzheimer’s disease report
- Introduction
- Executive Summary
- Alzheimer’s Disease (AD): Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Alzheimer’s Disease (AD) – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Alzheimer’s Disease (AD) Collaboration Deals
- Late Stage Products (Phase III)
- BAN2401: Eisai
- Mid Stage Products (Phase II)
- Bryostatin-1: Neurotrope
- Early Stage Products (Phase I)
- INB03 – INmune Bio
- Pre-clinical and Discovery Stage Products
- AZT-211: AZTherapies
- Inactive Products
- Alzheimer’s Disease (AD) Key Companies
- Alzheimer’s Disease (AD) Key Products
- Alzheimer’s Disease (AD)- Unmet Needs
- Alzheimer’s Disease (AD)- Market Drivers and Barriers
- Alzheimer’s Disease (AD)- Future Perspectives and Conclusion
- Alzheimer’s Disease (AD) Analyst Views
- Alzheimer’s Disease (AD) Key Companies
- Appendix
What are the key questions of the report?
- How many companies are developing Alzheimer’s Disease (AD) drugs?
- How many Alzheimer’s Disease (AD) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alzheimer’s Disease (AD)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alzheimer’s Disease (AD) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alzheimer’s Disease (AD) and their status?
- What are the key designations that have been granted to the emerging drugs?
Related Reports
Alzheimer’s disease Market
DelveInsight’ s Alzheimer’s disease Market Insights, Epidemiology and Market Forecast 2030 report provides an overview of disease and understanding of historical and forecasted epidemiology
Alzheimer’s disease Epidemiology
Alzheimer’s disease Epidemiology Forecast 2030 report delivers a detailed understanding of the disease, historical, and forecasted epidemiology in the 7MM.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/